ArticleArchives of medical science : AMS2026
Mendelian randomization analysis of 1,400 genetically predicted blood metabolites and ovarian cancer risk.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ovarian cancer is a malignant tumor and a major threat to women's health. Its development is influenced by diverse factors, among which metabolic dysregulation is increasingly recognized. However, evidence for a causal relationship between metabolic changes and ovarian cancer remains limited. This study aimed to identify potential biomarkers for early screening and a targeted therapeutic strategy. Material and methods: A genome-wide association study (GWAS) and a two-sample Mendelian randomization (MR) analysis were applied. Causality was primarily assessed using the random inverse variance weighted (IVW) method. Cross-validation was conducted with MR-Egger, weighted median, and weighted mode approaches. The MR-Egger intercept and Cochran's Q test were adopted to assess heterogeneity and pleiotropy. Pathway enrichment analysis was performed using MetaboAnalyst 6.0. Our research identified key metabolites as potential biomarkers for early screening and personalized therapy in ovarian cancer. By using MR, we established causal associations between ovarian cancer subtypes and plasma metabolites, offering valuable insights for clinical applications. Results: After false discovery rate (FDR) correction, one metabolite, 5-acetylamino-6-amino-3-methyluracil (AAMU), was found to be significantly associated with ovarian cancer risk. Also, significant metabolites were enriched in caffeine metabolism ( Conclusions: We integrated genomic and metabolomic analyses to reveal causal associations of metabolites with ovarian cancer and its subtypes. Certain metabolites were identified as prospective biomarkers for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.